ARPA-H gene editing program THRIVE awards $160 million to seven research teams tasked with building scalable base-editing ...
Ionis Pharmaceuticals is a leader in RNA-based therapies. Its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The ...
Human genetics has become the primary engine for identifying lipid-lowering drug targets and predicting therapeutic success or failure. Monogenic family studies and population-based sequencing ...
RNA has emerged as one of the most promising molecules in modern medicine, enabling advances from mRNA vaccines and gene ...
Persistence Market Research, a leading management consulting firm, has released this update on the gene editing market. Gene editing technologies enable ...
New England Biolabs (NEB®) has launched the NEBNext Companion Module for Oxford Nanopore Technologies Direct RNA Sequencing.
Persistence Market Research, a leading management consulting firm, has released this update on the gene editing market. Gene ...
University of Arkansas scientists study soybean cyst nematode proteins to develop gene-edited soybean varieties resistant to ...
Single-cell RNA-seq AI analysis has become the default way to make sense of the millions of expression measurements a single experiment can now generate. Turning raw sequencing counts into ...
The collaboration leverages Colossal's marsupial de-extinction and conservation biotechnology platform to save the Tasmanian devil from a contagious cancer that has driven 80% population declines ...
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results